If you search “best Selank supplier,” nearly every result is published by a company that sells Selank, or that earns a commission when you buy it. A ranking written by a seller is marketing, not evidence.

There is also a legal dimension. The Federal Trade Commission’s Rule on the Use of Consumer Reviews and Testimonials, 16 CFR Part 465, which took effect in October 2024, prohibits fake or misattributed reviews, undisclosed insider reviews, and company-controlled websites that present themselves as providing independent reviews of that company’s own products. A “top 10 Selank vendors” page run by a vendor is squarely the kind of content that rule targets.

So this guide answers a better question: how do you verify what is actually in the vial, regardless of whose name is on it?

That question has a concrete, checkable answer. A supplier either publishes a lot-specific certificate of analysis that identifies the molecule by mass, or it does not. That single test separates serious suppliers from the rest faster than any review score.

If you are new to this material, start with What Are Research Peptides? and Peptide Certificate of Analysis: How to Read a COA. For Selank’s own science, see What Is Selank?.

What Selank is, and the identity problem suppliers create

Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Structurally it is the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro tripeptide extension added at the C-terminus. That extension is the design feature: the native tuftsin fragment degrades rapidly, and Pro-Gly-Pro was added to slow enzymatic breakdown.

Property	Value
Sequence	Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)
Length	7 amino acids
Molecular formula	C₃₃H₅₇N₁₁O₉
Average molecular weight	≈ 751.9 g/mol
CAS number	129954-34-3
Parent compound	Tuftsin (TKPR), residues 289–292 of the IgG heavy chain
Developer	Institute of Molecular Genetics, Russian Academy of Sciences
FDA approval status	None

Sources: Selank entry with cited primary literature; ChemBlink CAS record; PubChem.

The analog problem: Selank is not the only thing sold as Selank

This is where supplier verification starts to matter. At least two related materials circulate under overlapping names:

• Selank — the unmodified heptapeptide above, ≈ 751.9 Da.
• N-acetyl Selank amidate (NA-Selank amidate) — the same backbone with an acetyl group on the N-terminus and an amide at the C-terminus. Both modifications are standard ways to block the chain ends against exopeptidase attack. These changes alter the molecular formula and shift the expected mass by roughly +41 Da relative to Selank (+42 Da for acetylation, −1 Da for the C-terminal amide).

The two are different molecules with different expected masses. They are routinely listed on vendor sites under similar names, sometimes with the same product photography, and sometimes with research citations that belong to the unmodified peptide. If your protocol specifies one, a vial of the other invalidates the work.

Note on the mass figures: The ≈ +41 Da shift is calculated from the standard acetylation and amidation mass changes, not taken from a published analytical paper. Treat it as an expected value to compare against the supplier’s own stated expected mass, not as an independent standard. Always use the expected mass printed on the COA for that specific product.

A related naming issue affects Semax, which comes from the same research tradition and is also sold in both plain and N-acetyl forms. The verification logic in this guide applies equally there.

Why a 41 Da difference is detectable

For a peptide this small, a 41 Da shift is roughly 5% of the total mass. That is trivially resolvable on any functioning mass spectrometer. There is no technical excuse for a supplier being unable to tell you which molecule it shipped. If a certificate reports a measured mass at all, the answer is already on the page. For the difference between the two testing methods, see HPLC vs. LC-MS: Understanding Peptide Purity and Identity Testing.

What the published research actually contains

Understanding the evidence base matters for supplier evaluation, because the gap between what the literature says and what product pages claim is itself a red flag.

The primary literature is small, mostly Russian, and mostly preclinical

Study	Model	Reported finding
Zozulia AA, et al. 2008 · Zh Nevrol Psikhiatr Im S S Korsakova 108(4):38–48	Human, generalized anxiety disorder and neurasthenia	The most-cited human study; compared Selank with medazepam in a small patient group
Uchakina ON, et al. 2008 · Zh Nevrol Psikhiatr Im S S Korsakova 108(5):71–75	Human, anxiety-asthenic disorders	Reported immunomodulatory effects, including cytokine changes
Inozemtseva LS, et al. 2008 · Dokl Biol Sci 421:241–243	Rat	Reported changes in hippocampal BDNF expression after intranasal administration
Kost NV, et al. 2001 · Bioorg Khim 27(3):180–183	In vitro, human serum	Selank and Semax inhibited enkephalin-degrading enzymes
Narkevich VB, et al. 2008 · Eksp Klin Farmakol 71(5):8–12	Mouse (BALB/c, C57Bl/6)	Reported changes in brain monoamine content
Sarkisova KI, et al. 2008 · Zh Vyssh Nerv Deiat 58(2):226–237	Rat (WAG/Rij, Wistar), mouse	Examined depression-like behaviors in animal models
Semenova TP, et al. 2010 · Eksp Klin Farmakol 73(8):2–5	Rat	Examined learning and memory parameters

What does not exist

This list is as important as the one above, and it is what most supplier pages omit:

• No FDA approval. Selank is not approved by the U.S. Food and Drug Administration for any indication.
• No large Western randomized controlled trials. The human data are limited to small studies, largely published in Russian-language journals, several of which are difficult to obtain in full text and were not conducted to the registration standards used for drug approval.
• No established safety profile for use outside a laboratory. There is no body of published pharmacovigilance data of the kind that supports an approved medicine.
• No consensus mechanism. GABAergic modulation, enkephalin-enzyme inhibition, and BDNF effects have each been reported, but they remain hypotheses under investigation rather than established pharmacology.

Why this matters when you read a product page

A supplier that writes “Selank has been studied for effects on anxiety” is doing something specific. In its August 2026 warning letter to Peak Performance Peptides, FDA cited exactly this phrasing pattern — “Studied for effects on glycemic control and insulin sensitivity” — as evidence that products were intended for human use, notwithstanding “research use only” labels. Under 21 CFR 201.128, intended use can be established from a seller’s own promotional material.

So when you evaluate a Selank supplier, outcome-flavored claims on the product page are not a sign of scientific sophistication. They are a sign the seller may be creating regulatory exposure for itself, which is worth knowing before you build a supply relationship around it.

This section summarizes published findings for research context only. It is not a description of effects in people and contains no guidance on use.

The verification framework: three questions a COA must answer

Most disputes about peptide quality collapse once you separate three questions that suppliers habitually merge into one number.

Question	What it asks	Method	Typical reporting
Identity	Is this the right molecule?	Mass spectrometry (MS, LC-MS, MALDI-TOF)	Expected mass vs. measured mass
Purity	What fraction of the peptide material is the target?	Reverse-phase HPLC	Percentage + chromatogram
Content	How much actual peptide is in the vial?	Net peptide content, amino acid analysis, or nitrogen determination	Percentage of gross vial weight

These are independent. A sample can be 99% pure and be the wrong molecule, because HPLC purity measures homogeneity, not identity. A vial can contain the right molecule at high purity and still hold far less peptide than the label says, because lyophilized peptide carries water, residual salts, and trifluoroacetate or acetate counter-ions. Net peptide content for a TFA salt commonly runs well below the gross weight; the exact figure depends on the peptide and the salt form, which is why it must be measured and stated rather than assumed.

The practical consequence: a product page advertising “99% purity” with no identity result and no content figure has answered one third of the question and implied it answered all three.

The Selank COA checklist

• The exact molecule is named on the certificate itself — “Selank” or “N-acetyl Selank amidate,” not just the product’s marketing name.
• An expected mass or molecular formula is stated. For unmodified Selank, ≈ 751.9 Da average mass (C₃₃H₅₇N₁₁O₉). The acetylated, amidated form should be roughly 41 Da higher.
• A measured mass is reported alongside the expected mass, with the observed ions or a deconvoluted value, not merely a pass/fail stamp.
• The lot or batch number on the COA matches the number on your vial. This is the single most-skipped check.
• An HPLC chromatogram is included, not just a purity percentage. A number without a trace cannot be assessed.
• Net peptide content is stated separately from purity.
• The testing laboratory is named, with a report date and a way to authenticate the document.
• The COA date is close to the manufacturing date, and the document is not years older than the lot.

Expected mass spectrometry values

Selank is small enough that it usually appears in electrospray MS at low charge states. Approximate values for the protonated forms:

Charge state	Selank (≈ 751.9 Da)	N-acetyl Selank amidate (≈ 792.9 Da)
[M+H]⁺	≈ 752.9 m/z	≈ 793.9 m/z
[M+2H]²⁺	≈ 377.0 m/z	≈ 397.5 m/z

These are illustrative average-mass calculations, not reference standards. Monoisotopic values run lower, and sodium or potassium adducts will add roughly 22 and 38 Da respectively to the singly charged ion. Compare against the expected mass the supplier’s own certificate states.

Red flags on a Selank COA

• No identity test at all — purity only.
• The certificate names no specific molecule, just “Selank” with no form specified.
• No lot number, or a lot number that does not match your vial.
• The same COA image appears across multiple products or multiple years.
• Purity stated to an implausible precision (“99.98%”) with no chromatogram.
• The lab is unnamed, or named but with no verifiable report ID.
• The certificate is a photograph or a low-resolution screenshot rather than a document.
• Net peptide content is absent, or purity is presented as though it were content.

A clean COA documents what was in a tested sample. It does not make a research chemical safe, suitable for any use in people, or legal to market as a drug. Peptides Exchange publishes lot certificates on our Certificates of Analysis page [CONFIRM: that the current Selank lot COA states the specific form, an expected mass, a measured mass, and net peptide content — if it does not, this checklist is one our own certificate fails].

How to read “third-party tested” claims

“Third-party tested” has no legal definition in this market. It is a marketing phrase, and its meaning ranges from rigorous to meaningless depending on who did the testing and who chose the sample.

Four tiers of testing claim, from weakest to strongest

1. Unsupported claim. The phrase “third-party tested” appears on the site with no document attached. This carries no information.
2. In-house testing presented as third-party. The analysis was run by the manufacturer or by a lab it owns. The result may be accurate, but no independent party verified it. Check whether the lab name on the report is a related company.
3. Independent lab, supplier-selected sample. A genuinely separate lab tested a sample the supplier chose and sent. This is the common case and is meaningfully better than nothing, but the supplier controlled which material was tested.
4. Independent lab, lot-specific, buyer-verifiable. The certificate ties to the lot you received, names the lab, and carries a report ID you can check with that lab directly. This is the standard worth holding out for.

Questions that separate the tiers

• Who owns the lab? Search the lab’s name. If it shares an address, ownership, or branding with the supplier, it is not independent.
• Can the report be authenticated? Many analytical labs serving this market issue report IDs that can be looked up on the lab’s own site. If no verification path exists, you are trusting a PDF that anyone could edit.
• Does the report cover your lot? A “representative” or “sample” COA tests material that is not yours.
• What was actually tested for? A report showing only HPLC purity is not a full characterization, whoever ran it.
• How old is the report? Peptides degrade. A certificate from a lot manufactured three years ago says little about current stock.

On accreditation

Some labs hold ISO/IEC 17025 accreditation, the international standard for the competence of testing and calibration laboratories. Accreditation means an independent accreditation body has assessed the lab’s methods, equipment, and quality systems for the specific tests in its scope.

Two caveats are worth holding onto. First, accreditation is granted for a defined scope — a lab accredited for one method is not thereby accredited for every test it offers, so a general claim of accreditation does not tell you the specific analysis on your COA was within scope. Second, accreditation describes the laboratory, not the material. An accredited lab can accurately characterize a sample that has nothing to do with the vial you received.

On GMP claims

Suppliers in this market frequently advertise “GMP-grade,” “GMP-manufactured,” or “produced in a GMP facility.” Read these carefully:

• Good Manufacturing Practice requirements under 21 CFR Parts 210 and 211 apply to finished pharmaceuticals, with separate expectations for active pharmaceutical ingredients.
• A facility may operate GMP lines for some products and non-GMP lines for others. “Made in a GMP facility” is not the same as “this lot was made under GMP.”
• Research chemicals sold for laboratory use are generally not manufactured as drug products, and a GMP claim attached to a product explicitly labeled research-use-only sits awkwardly with that labeling.
• Ask which standard, which certifying or inspecting body, and whether documentation covers your specific lot.

The broader checklist in Best Peptide Blend Suppliers in 2026: How to Verify Third-Party Testing, COAs, and GMP Claims goes further into GMP and testing claims, and CJC-1295 Suppliers: One Name, Two Different Molecules works through a case where two molecules share a single product name — the same failure mode as Selank and its acetylated analog.

Regulatory status in 2026

Not an approved drug. Selank is not approved by the U.S. Food and Drug Administration for any use. Material sold under this name is not equivalent to, and is not a substitute for, any approved medicine. No claim of therapeutic benefit can lawfully be made for it in the United States.

Not on FDA’s 503A compounding lists. As of this writing, Selank does not appear in Category 1, 2, or 3 of FDA’s 503A bulk drug substances categories, nor on the 503A bulks list. Absence from these lists is not permission. It means FDA has not evaluated the substance in that framework, which leaves its compounding status unresolved rather than approved.

For context on how quickly this area moves: on April 15, 2026, FDA announced it would remove 12 peptides — including Semax, BPC-157, and MOTS-c — from Category 2 ahead of Pharmacy Compounding Advisory Committee review (Frier Levitt; National Law Review). Even for those substances, removal from Category 2 is not approval and does not by itself make them eligible for compounding under section 503A.

“Research use only” is not a shield. This is the most consequential point for anyone choosing a supplier. FDA evaluates intended use from the totality of a seller’s conduct, not from a disclaimer. Recent warning letters to research-peptide sellers establish the pattern:

Warning letter	Date	What FDA cited
Peak Performance Peptides	Aug. 24, 2026	Outcome-flavored product claims (“Studied for effects on …”), plus sale of bacteriostatic water for reconstitution, as evidence of intended injectable human use despite RUO labeling
Pinnacle Professional Research d/b/a Pinnacle Peptides	Dec. 12, 2025	Marketing of unapproved new drugs
Summit Research Peptides	Dec. 10, 2024	Website content establishing human-use intent notwithstanding research-use disclaimers

Under 21 CFR 201.128, intended use may be shown by the seller’s own labeling, advertising, and surrounding circumstances. Dosing language, benefit claims, testimonials, before-and-after imagery, and bundled injection supplies have all been treated as such evidence.

What this means when you choose a supplier. A vendor whose product pages carry effect claims or supply injection consumables alongside research chemicals is operating in a posture FDA has repeatedly cited. Beyond the compliance question, such a supplier may face enforcement that interrupts availability of material your work depends on.

Reviews and rankings. The FTC’s 16 CFR Part 465 prohibits fake, undisclosed-insider, and misattributed reviews, and company-controlled sites posing as independent reviewers. This is why this guide publishes a method rather than a ranking.

Sport. Researchers working with athlete populations should note that the World Anti-Doping Agency’s Prohibited List is revised annually and that substances may be captured by its catch-all provisions even when not named individually. Verify the current list directly rather than relying on secondary summaries.

State law and importation. Several states regulate research chemical sales separately, and customs authorities may detain shipments of unapproved drugs. Institutions and individual researchers are responsible for confirming the rules that apply to them.

This section is general information, not legal advice. Peptide regulation changed repeatedly across 2025 and 2026. Verify current status on FDA’s own pages before relying on anything described here.

Frequently asked questions

Who is the best Selank supplier in 2026?

We do not publish a ranking, and we would treat any such list with suspicion when the publisher sells the product. The useful question is whether a given supplier provides a lot-specific COA that names the exact molecule, states an expected mass, reports a matching measured mass from an identifiable laboratory, and gives net peptide content separately from purity. A supplier that does all of that is verifiable. One that does not is asking for trust it has not evidenced.

What should a Selank COA show?

At minimum: the specific form (Selank or N-acetyl Selank amidate), an expected mass or formula, a measured mass, HPLC purity with a chromatogram, net peptide content, the lot number matching your vial, the testing lab’s name, and a report date.

What is the molecular weight of Selank?

Approximately 751.9 g/mol for the unmodified heptapeptide (C₃₃H₅₇N₁₁O₉, CAS 129954-34-3). N-acetyl Selank amidate is a different molecule with a mass roughly 41 Da higher.

Is N-acetyl Selank amidate the same as Selank?

No. It carries an N-terminal acetyl group and a C-terminal amide. Those modifications change the formula and the expected mass. Research citations for one do not transfer to the other.

Does high HPLC purity mean I received Selank?

No. HPLC measures how homogeneous a sample is, not what it is. Identity requires mass spectrometry. A 99% pure sample of the wrong peptide is still the wrong peptide.

Is Selank FDA approved?

No. It is not approved for any use in the United States, and it does not appear on FDA’s 503A compounding category lists.

Does “third-party tested” mean anything legally?

The phrase has no legal definition in this market. What matters is which laboratory ran the analysis, whether that laboratory is independent of the supplier, whether the report covers your specific lot, and whether you can authenticate the report with the lab.

Related articles

• What Is Selank?
• What Is Semax?
• HPLC vs. LC-MS: Understanding Peptide Purity and Identity Testing
• Peptide Certificate of Analysis: How to Read a COA
• Best Peptide Blend Suppliers in 2026: How to Verify Third-Party Testing, COAs, and GMP Claims
• What Are Research Peptides?
• What Are Peptides?
• Certificates of Analysis

References

1. Zozulia AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38–48. PubMed 18454096
2. Uchakina ON, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71–75. PubMed 18577961
3. Inozemtseva LS, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241–243. PubMed 18841804
4. Kost NV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim. 2001;27(3):180–183. PubMed 11443939
5. Narkevich VB, et al. Effects of heptapeptide selank on the content of monoamines in BALB/C and C57Bl/6 mice brain structures. Eksp Klin Farmakol. 2008;71(5):8–12. PubMed 19093364
6. Sarkisova KI, et al. Effects of selank on depression-like symptoms in rats and mice. Zh Vyssh Nerv Deiat Im I P Pavlova. 2008;58(2):226–237. PubMed 18661785
7. Semenova TP, et al. Comparative study of the effects of selank and tuftsin on learning and memory. Eksp Klin Farmakol. 2010;73(8):2–5. PubMed 20919548
8. U.S. FDA. Warning Letter: Peak Performance Peptides, MARCS-CMS 735127, August 24, 2026. fda.gov
9. U.S. FDA. Warning Letter: Pinnacle Professional Research d/b/a Pinnacle Peptides, MARCS-CMS 719337, December 12, 2025. fda.gov
10. U.S. FDA. Warning Letter: Summit Research Peptides, MARCS-CMS 695607, December 10, 2024. fda.gov
11. U.S. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A. fda.gov · 503A categories PDF
12. 21 CFR § 201.128 — Meaning of “intended uses.” eCFR
13. 21 CFR Part 211 — Current Good Manufacturing Practice for Finished Pharmaceuticals. eCFR
14. Federal Trade Commission. Trade Regulation Rule on the Use of Consumer Reviews and Testimonials, 16 CFR Part 465. ftc.gov
15. Frier Levitt. FDA to Remove 12 Popular Peptides from the Category 2 “Do Not Compound” List (2026). frierlevitt.com
16. National Law Review. Tiny Chains, Big Changes? What FDA’s Latest Actions Mean for Peptide Compounding (2026). natlawreview.com
17. ISO/IEC 17025:2017 — General requirements for the competence of testing and calibration laboratories. iso.org
18. World Anti-Doping Agency. The Prohibited List. wada-ama.org
19. Selank — compound summary and cited primary literature. Wikipedia · ChemBlink CAS 129954-34-3 · PubChem

Research use disclaimer

All products sold by Peptides Exchange are intended for in-vitro laboratory research use only. They are not drugs, foods, dietary supplements, or cosmetics. They are not intended to diagnose, treat, cure, or prevent any disease, and must not be administered to humans or animals. This article is educational and describes published scientific literature and publicly available regulatory documents. It contains no instructions for use, no dosing information, and nothing in it should be read as medical, legal, or scientific advice for any application outside a controlled laboratory setting. Statements here have not been evaluated by the FDA. Purchasers must be qualified researchers who agree to handle materials in accordance with all applicable laws and institutional requirements.